Finance

Lists
Q3 2026 earnings • released • EPS miss -0.00%
See results
IPSC:NASDAQ
Century Therapeutics Inc
$1.65
+1.23%
(+0.020) 1D
Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IPSC...
Open
$1.62
High
$1.68
Low
$1.56
Mkt. cap
298.77M
Avg. vol.
1.01M
Volume
373.22K
52-wk high
$3.04
52-wk low
$0.44
EPS
-$0.90
Beta
1.78
Shares outstanding
181.08M
No. of employees
78
Open
$1.62
High
$1.68
Low
$1.56
Mkt. cap
298.77M
Avg. vol.
1.01M
Volume
373.22K
52-wk high
$3.04
52-wk low
$0.44
EPS
-$0.90
Beta
1.78
Shares outstanding
181.08M
No. of employees
78
News stories
From web sources and news partners
About Century Therapeutics Inc
CEO-
Employees78
Founded2018
HeadquartersPhiladelphia, Pennsylvania, United States
SectorHealth Care
IndustryBiotechnology
Websitecenturytx.com
Analyst ratings
Based on 3 analysts giving stock ratings to IPSC in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for IPSC in the last 3 months.
Highest
Current $1.65
$8.00 (+384.85%)
Average
$5.67 (+243.64%)
Lowest
$4.00 (+142.42%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$5.00
+203%
11/13/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$4.00
+142.4%
10/06/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$8.00
+384.8%
08/17/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
08/12/2026
Unknown Analyst
Clear Street
Buy
Maintained
$6.60
+300%
08/13/2026
William Maughan
Clear Street
Buy
Maintained
$6.60
+300%
03/13/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
-$0.11 / -$0.11
-0.00%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
22.53M
19.70M
17.10M
19.60M
Cost of revenue
22.53M
19.70M
17.10M
19.60M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.84M
5.88M
8.40M
7.73M
Operating expense
6.84M
5.88M
8.40M
7.73M
Total operating expenses
29.36M
25.57M
25.50M
27.32M
Operating income
-29.36M
-25.57M
-25.50M
-27.32M
Other non operating income
97.00K
103.00K
20.00K
-5.00K
EBT including unusual items
-34.42M
-19.24M
-21.64M
-34.55M
EBT excluding unusual items
-27.66M
-24.16M
-23.46M
-25.34M
Income tax expense
-
-68.00K
-
-
Effective tax rate
-
0.35%
-
-
Other operating expenses
-
-
-
-
Net income
-34.42M
-19.17M
-21.64M
-34.55M
Net profit margin
-
-
-
-
Earnings per share
-0.32
-0.25
-0.11
-0.11
Interest and investment income
1.60M
1.31M
2.02M
1.98M
Interest expense
-
-
-
-
Net interest expenses
1.60M
1.31M
2.02M
1.98M
Depreciation and amortization charges
-
-
-
-
EBITDA
-26.23M
-22.02M
-22.50M
-24.71M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps